Control Bionics Finalizes Placement of 3.42 Million New Shares, Expands Equity Base on ASX

Control Bionics Completes Share Placement and Updates Capital Structure

ASX-listed Control Bionics Limited (ABN 45 115 465 462) has finalized a securities placement that enhances its equity capital. On 21 July 2026, the company issued 3,419,993 fully paid ordinary shares at AUD $0.075 each as part of a securities purchase plan previously communicated to investors. This placement was first announced through an Appendix 3B filing on 25 June 2026, and the newly issued shares have now been formally admitted to quotation on the ASX under the security code CBL.

The placement’s timing and pricing align with Control Bionics’ capital management strategy. No further securities remain to be issued under the transaction referenced in the original Appendix 3B, confirming completion of the placement. Post-quotation, the company’s total issued capital comprises 445,317,670 fully paid ordinary shares, marking a substantial expansion of its equity base and bolstering working capital for operational and strategic initiatives.

Share Capital Composition Following July 2026 Placement

Following the issuance of 3.42 million new shares, Control Bionics now holds a quoted equity base of 445,317,670 ordinary fully paid shares on the ASX. This figure represents the total number of securities in the primary equity class after the 21 July 2026 placement. While the company has increased its shareholder base across different holding categories, it has not disclosed the specific distribution of new shares among recipients or the percentage holdings by category.

Besides quoted shares, Control Bionics maintains a portfolio of 39.8 million unquoted options spanning 13 option classes with varying exercise prices and expiry dates. These include options expiring in October 2026 at $0.10, as well as longer-term options expiring in November 2030 and August 2030 with exercise prices of $0.045. These options stem from prior capital raises, employee incentive plans, and other financing activities.

Details of Control Bionics’ Unquoted Options Portfolio

The company’s unquoted options represent a diverse set of instruments issued over several years, featuring different maturities and strike prices. The largest class comprises 21.35 million CBLAU options expiring in October 2026 with an exercise price of $0.10, presenting near-term conversion opportunities for investors. Other significant tranches include 8 million options expiring November 2030 at $0.045 and 2 million options expiring January 2028 at $0.1637, each offering different strategic value.

The variety of option tranches indicates staged capital raises and employee equity schemes aimed at supporting growth and talent acquisition. Exercise prices ranging from $0.045 to $0.22 suggest some options are currently out of the money relative to the $0.075 placement price, while others reflect historical pricing or strategic considerations. The company has not disclosed the number of holders per option series or the distribution of holdings by investor type.

Role of the Securities Purchase Plan in Capital Raising

The 21 July 2026 placement was conducted under a securities purchase plan, a common method for listed companies to raise capital while offering shareholders direct investment opportunities. This approach indicates Control Bionics’ intent to involve shareholders in its growth and capital requirements through a structured offer. Specific details on plan terms, subscription periods, or investment limits were not disclosed.

Securities purchase plans provide flexibility by enabling staged or targeted offers to defined investor groups. Control Bionics’ choice of this method over a simple placement or rights issue may reflect a strategy to maintain shareholder engagement or prioritize existing shareholders’ participation. The company did not reveal the allocation split between existing and new investors, nor whether the offer was oversubscribed or undersubscribed.

ASX Regulatory Compliance and Quotation Process

Control Bionics complied with ASX Listing Rules by lodging an Appendix 2A application to quote the new 3,419,993 ordinary shares. This filing confirms adherence to ASX disclosure and governance standards and provides verified details on issued capital, pricing, and issue date. The Appendix 2A is the standard procedure for obtaining ASX approval to quote newly issued securities.

The company’s ABN (45 115 465 462) and ASX code (CBL) were verified in the application. Shares were issued in Australian dollars at AUD $0.075 each, representing the consideration paid by investors. The company did not disclose any fees, commissions, or transaction costs related to the placement or quotation. All information is based on the Appendix 2A filing lodged on 21 July 2026.

Timeline of Announcements and Completion Status

This update relates to a transaction first announced via Appendix 3B on 25 June 2026 under the title "New - Proposed issue of securities - CBL," outlining the intention to issue 3,419,993 shares now quoted on the ASX. The company confirms no further securities remain to be issued to complete this transaction, indicating the capital raise is fully executed.

The process—from the 25 June announcement to the 21 July quotation—aligns with typical ASX timelines for share placements. Investors had prior visibility of the proposed issue and could evaluate its impact on capital structure. This update formally confirms transaction completion and that shares are now tradable on the ASX subject to normal market conditions.

Capital Raise Pricing and Market Implications

The AUD $0.075 issue price per share reflects Control Bionics’ valuation for new equity under the securities purchase plan. This price point offers insight into investor sentiment and company valuation assessment during June-July 2026. The company did not provide guidance on fair value, rationale for pricing, or any discount/premium relative to prior trading levels.

Investors tracking share price performance may compare the placement price against market prices to assess relative valuation. No information was disclosed on demand, cornerstone investors, or participant profiles. The successful placement completion suggests adequate investor interest to fully subscribe for the 3,419,993 shares, though oversubscription or allocation details were not provided.

Equity Dilution Risks from Options Portfolio

The substantial unquoted options portfolio poses dilution risks for ordinary shareholders if exercised. The 39.8 million options span 13 series with exercise prices near or below the $0.075 placement price. Notably, 21.35 million CBLAU options expiring October 2026 at $0.10 will either be exercised or expire shortly, potentially impacting capital inflows.

Multiple option tranches reflect past equity compensation and capital raising efforts. Investors should consider dilution potential, especially from large tranches like 8 million CBLAY options at $0.045 and 2 million CBLAI options at $0.1637. The company did not disclose likelihood of exercise, vesting conditions, or performance/employment requirements for these options.

Strategic and Operational Overview

This update focuses on capital structure and share placement details without providing information on Control Bionics’ business operations, revenue streams, product lines, or strategic goals. Investors seeking context on the capital raise’s purpose or use of proceeds should consult other public disclosures, presentations, or prior announcements. The company did not explicitly state the total capital raised, which can be approximated at AUD $256,499.48 (3,419,993 shares × $0.075).

Operating under ASX security code CBL, Control Bionics meets main board listing standards. The securities purchase plan indicates an active capital management approach addressing operational or strategic funding needs. Completion of this placement and ASX quotation demonstrates the company’s capacity to access capital markets and comply with regulatory requirements.